2026 Awardees

Kelly Monaghan, PhD
Viral Immunology & Intravital Imaging Section, National Institute of Neurological Disorders and Stroke (NINDS)
Mentor: Dorian McGavern, PhD

Dr. Monaghan’s postdoctoral research uncovered an unexpected vascular mechanism that protects the central nervous system (CNS) during viral infection. This work focuses on the dural venous sinuses, which form a highly permeable interface between the circulation and CNS borders. Using advanced imaging techniques, Dr. Monaghan discovered that specialized sinus endothelial cells continually remodel their boundaries to facilitate immune surveillance of the sinus wall.

This remodeling behavior, which depends on the protein RAMP2, increases during systemic lymphocytic choriomeningitis virus (LCMV) infection as antiviral immune cells accumulate at the sinuses. Disrupting RAMP2-dependent remodeling during LCMV infection altered local antiviral immune-cell behavior and increased viral invasion of the meninges, the membranes surrounding the brain and spinal cord. These findings demonstrate that dynamic remodeling of the sinus wall is an active component of antiviral protection. They also provide a new framework for understanding how blood vessels and immune cells cooperate to defend the brain’s borders and may inform new strategies to protect the CNS from blood-borne infections.

Kelsey Lowman
Viral Immunology & Immunity Unit, National Institute of Allergy and Infectious Diseases (NIAID)
Mentor:
Leah Katzelnick, PhD, MPH

Kelsey received her bachelor's and master's degrees from the University of Alabama in 2018, where she studied population genetics and the environmental drivers of cardiometabolic diseases. She then worked as a research assistant at the University of Alabama at Birmingham from 2018 to 2021, transitioning her focus to infectious disease research. Kelsey went on to complete her PhD at the University of Cambridge as a scholar in the NIH-Oxford-Cambridge Scholars Program, co-mentored by Dr. Leah Katzelnick (NIH/NIAID) and Professor Jonathan Heeney (Department of Veterinary Medicine, Cambridge). Her thesis research mapped the evolution of B cell reactivity following sequential dengue infection. She completed her PhD in July 2026 and is currently a postdoctoral fellow at the NIH in the Viral Epidemiology and Immunity Unit, where she continues to build on her doctoral work through their new Phase I dengue challenge trial.

2025 Awardees

Edward Partlow, PhD
Single Virion Biology and Biophysics Unit (SVBBU), National Institute of Allergy and Infectious Diseases (NIAID)
Mentor: Tijana Ivanovic, PhD

Ed Partlow is a postdoctoral IRTA fellow at NIH/NIAID in the lab of Tijana Ivanovic. Ed began performing research in his undergraduate studies, investigating viral protein biology with Destin Heilman at Worcester Polytechnic Institute in Worcester, MA. He then completed his doctoral thesis work at Cornell University in Ithaca, NY. Under the mentorship of Gunther Hollopeter, Ed used C. elegans genetics and structural biology to discover molecular details of the clathrin adaptor protein, AP2. Ed’s postdoctoral research at NIH focuses on the assembly of influenza filamentous virions and the impact of virion morphology on viral adaptation. Ed also researches the assembly and maturation of non-enveloped viruses such as mammalian orthoreovirus.

Ryan Burdick
HIV Dynamics and Replication Program, National Cancer Institute (NCI) - Frederick Campus
Mentor: Vinay K. Pathak, PhD

Mr. Burdick investigated the timing and location of HIV-1 capsid disassembly (uncoating) and its impact on the selection of viral DNA integration sites in the laboratory of Vinay Pathak, PhD, while enrolled as a graduate student in the Biological Sciences PhD program at the University of Maryland, Baltimore County. Building on his earlier discovery that intact HIV-1 cores enter the nucleus and uncoat near integration sites, he demonstrated that uncoating is triggered by the synthesis of long double-stranded viral DNA. He further proposed that nucleocapsid-mediated compaction regulates the internal pressure generated by the rigid DNA, ensuring that uncoating occurs only after reverse transcription is complete. Mr. Burdick also showed that uncoating occurs within interchromatin compartments enriched in RNA processing factors called nuclear speckles, and that viral DNA subsequently exits these compartments to integrate into nearby chromatin. In addition, he showed that small-molecule capsid inhibitors redirect uncoating to sites outside nuclear speckles, shifting integration away from speckle-associated chromatin domains and revealing that uncoating location dictates integration site selection. Collectively, his work provides new mechanistic insight into how the HIV-1 capsid orchestrates early steps of infection.

Our Speakers



Keynote Speaker
Rafi Ahmed, PhD
Professor, Department of Microbiology and Immunology, Emory University; Director, Emory Vaccine Center

Topic: Understanding T Cell Exhaustion: Implications for Immunotherapy

Dr. Rafi Ahmed is an internationally recognized immunologist whose pioneering research has profoundly shaped our understanding of immune memory and T cell exhaustion — concepts that are now foundational to cancer immunotherapy. Dr. Ahmed is Director of the Emory Vaccine Center at Emory University School of Medicine, co-leader of the Cancer Immunology Research Program at Winship Cancer Institute of Emory University, and a Georgia Research Alliance Eminent Scholar. Dr. Ahmed is a Member of the National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. He is a Fellow of the AACR Academy and the SITC Academy of Immuno-Oncology.

Bernard Moss, MD, PhD
Chief, Genetic Engineering Section; NIH Distinguished Investigator, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases

Topic: All Things Poxvirus: my 60 years of research inspired by Norman Salzman

Dr. Moss received his M.D. from the New York University School of Medicine, interned at the Children's Hospital Medical Center (Boston), and then earned a Ph.D. in biochemistry from the Massachusetts Institute of Technology. He became interested in viruses after joining NIH and is well known for studies on the cap structure of mRNAs, regulation of gene expression, replication cycle of poxviruses, virus defense molecules, and development and application of virus vectors. Dr. Moss has received numerous awards and prizes, including the Dickson Prize for Medical Research, the Invitrogen Eukaryotic Expression Award, the ICN International Prize in Virology, the Taylor International Prize in Medicine, the Bristol-Myers Squibb Award for Distinguished Achievement in Infectious Disease Research, the International Poxvirus, Asfarvirus and Iridovirus Lifetime Achievement Award and the ASM Lifetime Achievement Award. He was elected to the National Academy of Sciences, American Academy of Microbiology, Fellow of the American Association for the Advancement of Science, and president of the American Society for Virology. Dr. Moss is currently on the editorial boards of the Proceedings of the National Academy of Sciences, the Journal of Virology, and the NIH Catalyst. He is an adjunct professor at the University of Maryland.

Jason Brenchley, MD, PhD
Chief, Laboratory of Viral Diseases; Senior Investigator, Barrier Immunity Section, National Institute of Allergy and Infectious Diseases
Tribute Speaker - 2004 Norman P. Salzman Postdoctoral Award Recipient

Topic: The Gastrointestinal Microbiome and Progressive Immunodeficiency Lentiviral Infections

Dr. Brenchley received a master’s degree from Idaho State University in 1999 and received a Ph.D. from the University of Texas Southwestern Medical Center at Dallas in 2003. He joined NIH as a research fellow, studying immunopathogenesis and mucosal immunology in HIV-infected individuals. He became a tenure track investigator in the intramural program of NIAID in 2008 and was tenured in 2011. He has been the chief of the Lab of Viral Diseases since 2024.

Priyamvada Acharya, PhD
Professor, Departments of Surgery and Biochemistry, Duke University School of Medicine; Director, Division of Structural Biology, Duke Human Vaccine Institute; Director, Duke Center for HIV Structural Biology

Topic: Structures of Vulnerability: Viral Entry, Antibody Recognition, and Mechanisms of Broad Protection

Priyamvada Acharya received her Ph.D. in Biochemistry from the Centre for Cellular and Molecular Biology in Hyderabad, India. She joined the Structural Biology Section of the Vaccine Research Center at NIAID in 2005, where her work helped define how HIV-1 engages host receptors, how broadly neutralizing antibodies recognize conserved sites of vulnerability on the viral envelope glycoprotein, and how structural insights can inform vaccine and therapeutic development.

In 2018, Dr. Acharya joined Duke University to lead the Division of Structural Biology at the Duke Human Vaccine Institute. In 2022, Dr. Acharya founded the Duke Center for HIV Structural Biology, a multi-institutional NIH U54 center that integrates structural biology, immunology, virology, technology development, and scientific workforce development. She has also led multiple NIH-funded research programs and served as Chair of the NIH Macromolecular Structure and Function C Study Section from 2024 to 2026.

Jeffrey Cohen, MD
Chief, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases

Topic: Vaccines and Monoclonal Antibodies to Prevent Epstein-Barr Virus Infection/Disease

Jeff Cohen received his M.D. from Johns Hopkins University, was a resident in medicine at Duke University, and a clinical fellow in infectious diseases at the Brigham and Women’s Hospital. He came to NIH as chief of the Medical Virology Section in the Laboratory of Clinical Infectious Diseases and is now chief of the Laboratory of Infectious Diseases. His lab studies the pathogenesis and clinical aspects of human herpesviruses, especially Epstein-Barr virus and herpes simplex virus. The laboratory focuses on vaccine development, discovery of monoclonal antibodies to viral proteins, and identification of cellular mutations in patients with severe herpesvirus infections. Clinical studies include three ongoing trials of Epstein-Barr Virus nanoparticle vaccines developed in the lab, and studies of patients with severe virus infections.